The number and timing of prenatal visits has remained unchanged since 1930. The original 12 to 14 weeks schedule was implemented to address preeclampsia. During the pandemic, new approaches were taken to address scope of prenatal care and these changes have been viewed as sustainable. In 2020, ACOG collaborated with the University of Michigan and convened maternity care, public health, and pediatric experts as well as patient representatives to address care models for average risk patients (MiPATH). The outcome of this project determined that individualized plans based on individually assessed medical, social and structural determinants of health (SSDoH) were considered to be ideal. The resulting publication, reviewed below, outlines “the new MiPATH recommendations and to provide practical guidance on implementing them in routine practice.”
Note: In the new MiPATH recommendations, there are only 4 mandatory face-to-face visits: first prenatal visit | 28 weeks | 36 weeks | 39 weeks
Michigan Plan for Appropriate Tailored Healthcare in Pregnancy Prenatal Care Recommendations: A Practical Guide for Maternity Care Clinicians
The Michigan Plan for Appropriate Tailored Healthcare in Pregnancy Prenatal Care Recommendations (Research Plan)
ACOG Committee Opinion 798: Implementing Telehealth in Practice
MiPATH: Pregnancy and Postpartum Patient Resources
Are you an
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site